Windward Bio

Private

Clinical-stage immunology company developing long-acting antibody therapies for severe respiratory and immunological diseases, including an anti-TSLP antibody licensed from Kelun-Biotech and Harbour BioMed.

Company Info

Sector:Biotechnology — Immunology

Headquarters:Basel, Switzerland

Founded:2024

Website:windwardbio.com/

Funding Round:Series A

Total Funding:$200M

Clinical Development Pipeline

WIN378

Target: TSLP ligand

Asthma / COPD

Preclinical

Phase 1

Phase 2

Phase 3

Approved

WIN027

Target: TSLP x IL-13

Respiratory and dermatologic disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Luca Santarelli, M.D.

Founder, Chairman and Chief Executive Officer

Careers & Job Openings

See all open roles

All

Basel, Switzerland

Apply Now →